Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Gastrointestinal Stromal Tumors 3 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Neurofibrosarcoma 1 Neoplasms 1 Melanoma 1 Hemangiosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Doxorubicin 142 Ifosfamide 85 Radiotherapy 82 Cyclophosphamide 72 Gemcitabine 63 Filgrastim 54 pembrolizumab 43 pazopanib 40 Etoposide 39 Docetaxel 39 Vincristine 37 Trabectedin 37 Cisplatin 35 Nivolumab 32 Magnetic Resonance Spectroscopy 26 Irinotecan 26 Carboplatin 25 Surgical Procedures, Operative 24 Temozolomide 23 Radiation 22 Ipilimumab 22 Bevacizumab 20 Blood Specimen Collection 19 Granulocyte Colony-Stimulating Factor 18 Biopsy 18 eribulin 17 anlotinib 17 Sirolimus 17 Mesna 17 Melphalan 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × pexidartinib × Sarcoma × Clear all

NCT02584647 2025-03-21

PLX3397

Columbia University

Phase 1/2 Terminated

39 enrolled 13 charts

Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡